Press Releases

Summary ToggleProLung, Inc. Appoints Mark Anderson, CPA as Chief Financial Officer

March 28, 2018

ProLung, Inc. is focused on making a difference in time for lung cancer patients with its innovative predictive analytics technology and non-invasive tests for the risk stratification of indeterminate pulmonary nodules. Today ProLung announces the appointment of Mark V. Anderson, CPA as Chief Financial Officer.

Summary ToggleProLung Test™ by ProLung, Inc. named Finalist in 2018 Utah Innovation Awards

March 26, 2018

We are excited to announce our ProLung Test™ has been selected as a finalist in the Life Science-Biotech category for the 2018 Utah Innovation Awards, presented by Stoel Rives LLP and the Utah Technology Council! ProLung will be attending the Awards Dinner in Salt Lake City later this month.

Summary ToggleProLung, Inc. Appoints Rex Yung, MD as Chief Scientific Officer

March 19, 2018

ProLung, Inc., which is focused on making a difference in time for lung cancer patients with its innovative predictive analytics technology and non-invasive tests for the risk stratification of indeterminate pulmonary nodules, announces the appointment of Rex Yung, MD, FCCP as Chief Scientific Officer.

Summary ToggleProLung, Inc. Appoints Kristin M. Larson, NP, as Director of Clinical Affairs

March 12, 2018

ProLung, Inc., the world leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announces today the appointment of Kristin M. Larson, NP, to Director of Clinical Affairs.

Summary ToggleJerry Remy, Lung Cancer Survivor, and ProLung, Inc. Urge You to ''Get to Your Doctor''

March 07, 2018

Mr. Jerry Remy, the well-recognized broadcast voice of the Boston Red Sox, is a five-time lung cancer survivor.

Summary ToggleDr. Robin Smith, one of ProLung’s Board of Directors and CEO of CURA Foundation, featured on The View

March 05, 2018

Exciting news from one of our Board of Directors and CEO of CURA Foundation, Dr. Robin Smith, who is a driving force with the upcoming 4th Annual International "Unite to Cure" Conference at the Vatican in Rome.

Summary ToggleProLung, Inc. Appoints Andy C. Robertson, as Chief Marketing Officer

March 02, 2018

ProLung, Inc., the world leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announces that the company has promoted Andy C. Robertson to Chief Marketing Officer.

Summary ToggleProLung, Inc. Announces New Japanese Patent for Diagnosing a Malignant Lung Tumor

March 01, 2018

ProLung, Inc., the world leader in innovative predictive analytics technology and non-invasive tests for lung cancer, announces the Japan Patent Office has issued a Notice of Allowance for its Method for Diagnosing a Malignant Lung Tumor patent application.

Summary ToggleProLung, Inc. Announces Appointment of Neil Berkley to its Board of Directors

February 27, 2018

ProLung, Inc., the world leader in innovative predictive analytics technology and non-invasive tests for the risk stratification of lung cancer, announced today that Neil Berkley has joined the Company's Board of Directors.

Summary ToggleSteven C. Eror, President and CEO of ProLung, Inc., featured in PharmaVOICE 2018 Year in Preview

November 28, 2017

ProLung, Inc., the world leader in accurate, non-invasive, and radiation-free predictive analytics for rapid risk stratification of lung cancer, is pleased to share the PharmaVOICE “2018 Year in Preview: Treatment to Wellness” featuring ProLung president and CEO, Steven C. Eror.